RO7795081

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 Diabetes MellitusRenal ImpairmentOverweight or Obesity

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

1

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 3

52

Maridebart Cafraglutide

Amgen

Phase 3

33

Retatrutide

Eli Lilly

Phase 3

14

Elecoglipron

AstraZeneca

Phase 3

55

GZR4

GGan and Lee Pharmaceuticals, USA

Phase 3

56

TG103

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 3

27

Adenocard

Astellas

Preclinical

18

NOVOLIN R

Novo Nordisk

Preclinical

19

RO7795081

Roche

Phase 2

110

Dostinex

Pfizer

Preclinical

—Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Medication1 trial

A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081

Completed·Roche·Phase 1·NCT06809608·36 enrolled

Renal Impairment1 trial

A Two-part, Non-randomized, Open-label, Parallel-group Study to Assess the Effect of Renal Impairment on the Pharmacokinetics and Safety of RO7795081 Following a Single Oral Dose of RO7795081

Recruiting·Roche·Phase 1·NCT07741604·60 enrolled

Obesity1 trial

A Phase I, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Fixed-Sequence Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Orally Administered RO7795081 and the Effect of Steady-State Dose of Orally Administered RO7795081 on the Pharmacokinetics of Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Active, not recruiting·Roche·Phase 1·NCT06982131·40 enrolled

Obesity or Overweight1 trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 38 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Completed·Roche·Phase 2·NCT07081958·352 enrolled

Overweight or Obesity1 trial

An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

Active, not recruiting·Roche·Phase 1·NCT07499050·30 enrolled

1 more indication

Type 2 Diabetes Mellitus1 trial

A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus

Active, not recruiting·Roche·Phase 2·NCT07112872·240 enrolled

Details

Drug Info

Related News